Does Administration of Recombinant Lecithin:Cholesterol Acyl Transferase (rLCAT) Lead To Reduction in Inflammatory Markers and Changes in Plaque Composition and Cell Cholesterol Content in Patients With Peripheral Vascular Disease

Trial Profile

Does Administration of Recombinant Lecithin:Cholesterol Acyl Transferase (rLCAT) Lead To Reduction in Inflammatory Markers and Changes in Plaque Composition and Cell Cholesterol Content in Patients With Peripheral Vascular Disease

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs MEDI 6012 (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Sponsors AlphaCore Pharma
  • Most Recent Events

    • 28 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top